BIOCARE INFUSION
ONCOLOGY & THERAPEUTICS

RHEUMATOLOGY ORDER SET

FAX: 470.922.3656 | **PHONE:** 470.377.6400

PATIENT INFORMATION:

Fax completed form, insurance information, and clinical documentation to 470.922.3656

Patient Name: _____ DOB: _____ Phone: _____

Patient Status: ☐ New to Therapy ☐ Continuing Therapy **Next Treatment Date:**

MEDICAL INFORMATION

Patient Weight: _____ lbs. Patient Height: _____ Allergies: _____

ICD-10: _____ **Diagnosis**:

☐ Rheumatoid Arthritis, Unspecified
☐ Unspecified Iridocyclitis
☐ Arthropathic Psoriasis, Unspecified
☐ Rheumatoid Arthritis with Rheumatoid Factor, Unspecified
☐ Rheumatoid Arthritis without Rheumatoid Factor, Unspecified
☐ Wegener's granulomatosis
☐ Ankylosing Spondylitis, Unspecified
☐ Gout
☐ Systemic Lupus Erythematosus
☐ Other: _____

THERAPY ORDER

Drug	Dosing	Refill
Actemra	☐ 4 mg/kg IV every 4 weeks for _____ doses, then followed by 8mg/kg every 4weeks thereafter ☐ 4 mg/kg IV every 4 weeks ☐ 8 mg/kg IV every 4 weeks ☐ Other dose: _____ mg IV every 4 weeks	
Cimzia	☐ Initial Dose: 400mg subcutaneously at weeks 0, 2, and 4 weeks Maintenance Dose: ☐ 200mg subcutaneously Q 2 weeks **OR** ☐ 400mg subcutaneously Q 4 weeks	
Krystexxa	☐ 8mg IV every 2 weeks	
Immunoglobulin	☐ IV ☐ SubQ _____ gm/kg x _____ day(s) **OR** divided over ____ day(s) Brand: _____ _____ mg/kg x _____ day(s) **OR** divided over ____ day(s) (Biocare Infusion to choose if not indicated) Frequency: Every _____ weeks or _____	
Orencia	Orencia Dose: _____ mg IV Frequency: ☐ Every 4 weeks OR ☐ 0, 2, 4 weeks, and every 4 weeks thereafter	
Simponi Aria	☐ Initial Dose: 2mg/kg at weeks 0, 4, and then every 8 weeks ☐ Maintenance Dose: 2mg/kg every 8 weeks	
Stelara	Initial Dose: ☐ 45mg subcutaneously initially, 4 weeks later, followed by 45mg every 12 weeks ☐ 90mg subcutaneously initially, 4 weeks later, followed by 90mg every 12 weeks Maintenance Dose: ☐ 45mg subcutaneously every 12 weeks Maintenance Dose: ☐ 90mg subcutaneously every 12 weeks	
Infliximab	Dose: _____ mg/kg ☐ May substitute biosimilar per insurance requirement Frequency: ☐ Every _____ weeks *For Biocare Infusion use*. Brand: _____ ☐ 0, 2, 6, then every 8 weeks ☐ Do not substitute. Brand: _____	
Rituximab	Dose: ☐ 1000mg ☐ Other: _____ ☐ May substitute biosimilar per insurance requirement ☐ 375mg/m2 *For Biocare Infusion use*. Brand: _____ Frequency: ☐ One time dose ☐ Weekly x4 weeks ☐ Day 0, repeat dose in 2 weeks ☐ Do not substitute. Brand: _____	
Saphnelo	☐ 300mg IV every 4 weeks	

Premedication orders: Tylenol ☐ 1000mg ☐ 500mg PO, please choose one antihistamine:
☐ Diphenhydramine 25-50mg PO/IV ☐ Loratadine 10mg PO ☐ Cetirizine 10mg PO ☐ Cetirizine 10mg IVP
Additional premedications: ☐ Solu-Medrol _____ mg IVP ☐ Solu-Cortef _____ mg IVP ☐ Other _____
Lab orders: _____ **Lab frequency:** _____ ☐ Yearly TB QFT (optional) ☐ Baseline HepBcAB total

PROVIDER INFORMATION

By signing this form and utilizing our services, you are authorizing *Biocare Infusion,* and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient

Provider Name: _____ Signature: _____ Date: _____
Provider NPI: _____ Phone: _____ Fax: _____ Contact Person: _____
☐ Opt out of Biocare Infusion selecting site of care (if checked, please list site of care):

PREFERRED LOCATION

City: _____ State: _____ *View our locations here:*

BIOCARE INFUSION
ONCOLOGY & THERAPEUTICS

COMPREHENSIVE SUPPORT FOR RHEUMATOLOGY THERAPY

PATIENT INFORMATION:

Patient Name: _____ DOB: _____

REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

☐ Include signed and completed order (MD/prescriber to complete page 1)

☐ Include patient demographic information and insurance information

☐ Include patient's medication list

☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance benefits, or contraindications to conventional therapy

☐ For biologic orders, has the patient had a documented contraindication/intolerance or failed trial of a conventional therapy (i.e., steroids)? ☐ Yes ☐ No
If yes, which drug(s)? _____

☐ For biologic orders, does the patient have a contraindication/intolerance or failed trial to any other biologic? ☐ Yes ☐ No
If yes, which drug(s)? _____

☐ Include labs and/or test results to support diagnosis

☐ *If applicable* - Last known biological therapy: _____ and last date received: _____. If patient is switching to biologic therapies, please perform a wash-out period of _____ weeks prior to starting ordered biologic therapy.

☐ Other medical necessity: _____

REQUIRED PRE-SCREENING (BASED ON DRUG THERAPY)

☐ **TB screening test completed within 12 months - attach results**
Required for: Actemra, Cimzia, infliximab, Stelara, Simponi Aria, Orencia
☐ **Positive** ☐ **Negative**

☐ **Hepatitis B screening (Hepatitis B surface antigen) - ☐ Positive ☐ Negative**
Required for: Actemra, Cimzia, infliximab, rituximab, Simponi Aria

Hepatitis B core antibody total (not IgM) - ☐ Positive ☐ Negative
Required for: rituximab

☐ **Serum immunoglobulins - attach results** *Recommended for: rituximab*

☐ **Baseline creatinine - attach results** *Required for: IVIG*

*If TB or Hepatitis B results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+)

Biocare Infusion will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance